Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856266 | 1.00 | TAS2R14 (0.42) | TAS2R14DAGLACCR5HTR1ES1PR3 | |
| SCHEMBL3851445 | 0.86 | TAS2R14 (0.42) | TAS2R14DAGLACCR5LMNAGAA | |
| SCHEMBL3851544 | 0.83 | TAS2R14 (0.50) | TAS2R14CCR5HTR1ES1PR3LMNA | |
| SCHEMBL3855990 | 0.80 | TAS2R14 (0.52) | TAS2R14LMNASMN1; SMN2POLBCNR2 | |
| SCHEMBL3859964 | 0.79 | TAS2R14 (0.62) | TAS2R14LMNASMN1; SMN2POLBCNR2 | |
| SCHEMBL3860197 | 0.79 | TAS2R14 (0.65) | TAS2R14CNR2 | |
| SCHEMBL3854330 | 0.79 | TAS2R14 (0.50) | TAS2R14LMNASMN1; SMN2CNR2 | |
| SCHEMBL3853184 | 0.79 | TAS2R14 (0.50) | TAS2R14LMNAPOLBCNR2 | |
| SCHEMBL3851442 | 0.78 | TAS2R14 (0.39) | TAS2R14DAGLACCR5LMNAGAA | |
| SCHEMBL3852916 | 0.78 | TAS2R14 (0.54) | TAS2R14LMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | claimed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | claimed |
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | TAS2R14 4736/4885DAGLA 814/4885CCR5 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.